Development of autogenous vaccines for the control of amoebic gill disease in farmed salmon

阿米巴鳃病（AGD）是一种在包括苏格兰和爱尔兰在内的世界各地养殖鲑鱼中出现的新疾病。变形虫寄生在鱼的鳃上，引起炎症，导致鱼窒息。该项目汇集了斯特林大学水产养殖研究所在年龄、性别和疾病方面具有专门知识的科学家;苏格兰最大的养殖鲑鱼生产商苏格兰海洋收获公司;以及专门生产特定农场“自体”疫苗的中小企业里奇韦生物制品有限公司。该财团的目标是采样，培养和在苏格兰杀死鱼类的阿米巴原虫，然后根据这些分离的阿米巴原虫开发疫苗。这些疫苗将在实验室环境中进行鲑鱼试验。在实验室中证明有效的实验疫苗将用于在海笼中对鱼类进行疫苗接种，以评估自然暴露于阿米巴虫后鱼类的疫苗效力。

Amoebic gill disease (AGD) is a new disease emerging in farmed salmon across the world including Scotland and Ireland. The amoeba colonise the gills of fish causing inflammation which can lead to suffocation of the fish. The project brings together scientists with expertise in AGD at the Institute of Aquaculture, University of Stirling; Marine Harvest Scotland, the biggest producer of farmed salmon in Scotland; and Ridgeway Biologicals Ltd, an SME which specialises in the manufacture of farm-specific "autogenous" vaccines. The consortium aims to sample, culture and characterise amoebae which are killing fish in Scotland and then develop vaccines based on these isolated amoeba. The vaccines will be tested in salmon in experimental trials in a laboratory environment. Experimental vaccines that prove effective in the laboratory will be used to vaccinate fish in sea cages to assess vaccine efficacy in fish following natural exposure to amoeba.